Targeting DNA Repair Pathways Could Enhance Cancer Immunotherapy Effectiveness
TL;DR
Targeting DNA repair pathways could give immunotherapy an edge, expanding its effectiveness for more patients and advancing cancer treatment options.
A study shows disrupting tumor DNA repair mechanisms enhances immunotherapy, with companies like Calidi Biotherapeutics exploring complementary approaches like oncolytic virus treatments.
This research offers hope for improving cancer immunotherapy, potentially making treatments more accessible and effective for a broader range of patients worldwide.
Scientists are boosting cancer immunotherapy by targeting how tumors repair DNA damage, with innovative approaches like oncolytic viruses being studied by Calidi Biotherapeutics.
Found this article helpful?
Share it with your network and spread the knowledge!
A newly published study indicates that cancer immunotherapy could be enhanced by targeting pathways that tumor cells use to repair DNA damage. The research shows that disrupting these DNA damage response (DDR) mechanisms could make immunotherapy more effective for a broader range of patients.
The study's findings suggest that when tumor cells experience DNA damage, they activate specific repair pathways that help them survive. By targeting these pathways, researchers believe they can make cancer cells more vulnerable to immunotherapy treatments, which work by boosting the body's immune system to recognize and attack cancer cells.
As DDR-targeting therapies undergo further study, other complementary approaches are also being explored. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are investigating additional methods, including oncolytic virus treatments, which use modified viruses to selectively infect and destroy cancer cells.
This research is important because while immunotherapy has revolutionized cancer treatment for some patients, many others do not respond to current immunotherapies. The approach of targeting DNA repair pathways represents a potential strategy to expand the benefits of immunotherapy to more cancer patients. The implications extend across the oncology field, potentially leading to more effective combination therapies and improved patient outcomes.
For more information about developments in the biotechnology sector, visit https://www.BioMedWire.com. Additional details about terms of use and disclaimers can be found at https://www.BioMedWire.com/Disclaimer.
Curated from InvestorBrandNetwork (IBN)
